AcelRx Pharmaceuticals Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AcelRx Pharma (ACRX) Misses Q1 EPS by 3c
May 11, 2020 4:32 PM EDTAcelRx Pharma (NASDAQ: ACRX) reported Q1 EPS of ($0.20), $0.03 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $386 thousand versus the consensus estimate of $1.98 million.
Cash, cash equivalents and short-term investments balance of $52.7 million as of March 31, 2020;
"During this... More
